Clinical Trial Search

Primary: Rate of Moderate or Severe COPD Exacerbations in Participants With Moderate to Very Severe COPD. — 1.75; 2.11 exacerbations per year — p=0.1042

Primary: Exacerbation Rate — 1.20; 1.31 exacerbation per patient year — p=0.7282

Primary: Clinical Exacerbation of COPD (CE-COPD) Rate: Percentage of Participants Who Experienced at Least 1 Moderate or Severe CE-COPD — 28 percentage of participants

Primary: All-cause Mortality, Symptomatic Venous Thromboembolism Recurrence, or Need for Readmission. — 110; 107 Participants

Primary: Number of Patients Who Were Cured — 91; 117 Participants — p=<0.05

Primary: Mean Rate of Moderate or Severe Acute Exacerbations of Chronic Obstructive Pulmonary Disease (AECOPD) — 0.78; 0.71 AECOPD events/year — p=0.645

Primary: Dyspnea Intensity — 8.0; 6.5; 7.75; 5 units on a scale

Primary: Healthcare Utilization — 1080; 920 Participants — p=0.041

Primary: Change From Baseline in Specific Imaging Airway Volume (siVaw), Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured…

Primary: Number of Par. With Chronic Obstructive Pulmonary Disease (COPD) EXs Requiring Hospitalization That Occurred >21 Days Post-discharge/Physician's Office Visit for a COPD…

Primary: Rate of Moderate or Severe Exacerbations in Participants in the High Stratum — 1.71; 1.40 Moderate/severe exacerbations per year — p==0.036

Primary: Time to All-cause Mortality or Re-hospitalization During the 180 Days Post-randomization. — 54; 55 Days to event — p=<0.1

Primary: Time to the Next COPD Exacerbation — 72; 58 days — p=0.764

Primary: Percentage of Sputum Samples Positive for Bacterial Pathogens as Identified by Bacteriological Methods, in Any Stable COPD Patients and During AECOPDs — 74.2; 78; 94.6…

Primary: Annual COPD Exacerbation Rate Over 56 Weeks Treatment Comparison for Patients With Baseline EOS>=220/uL — 0.99; 1.21; 1.09; 1.17 Exacerbations per year — p=0.0638

Primary: Percentage Decrease of Sputum Eosinophils From Baseline to End of Therapy (6 Months) — 11.28; 7.07 percentage

Primary: Annual COPD Exacerbation Rate Over 56 Weeks Treatment Comparison for Patients With Baseline EOS>=220/uL — 1.19; 1.03; 1.24 Exacerbations per year — p=0.6490

Primary: Number of Participants With Any Adverse Events (AEs) and Serious AEs (SAEs) — 120; 27 Participants

Primary: Change in FEV1 From Baseline to Day 5 or Baseline to Day 10 Measure: FEV1 Change in Forced Expiry Volume in 1 Second — 155.1; 100.8; 48.9; 106.3 mL

Primary: The Primary Efficacy Variable Was the AAC for Daily EXACT Scores During the 12-week Treatment Period. — 415.4; 391.7 Area Above Curve on Daily Exact Score — p=0.759

Primary: First Occurrence of (Moderate or Severe) COPD Exacerbation — 1277; 1414 number of first occurrences — p=<0.0001

Primary: Annualized Rate of Moderate or Severe Exacerbations — 0.80; 1.01 Exacerbations per year — p=0.011

Primary: The Rate of Moderate and Severe COPD Exacerbations Defined as: Worsening of ≥2 Major Symptoms or Worsening of 1 Major Symptom Together With ≥1 Minor Symptom for ≥2…

Primary: Change in Exhaled Breath Metabolites — 3298 breath metabolites

Primary: Number of Patients With Hospital Re-admission and Mortality — 84; 61 Participants

Primary: Number of PRN Respiratory Therapy Drugs Per Day (PRN Treatments With Short Acting Bronchodilators Via Nebulization Given by Respiratory Therapists). — 0.03 treatments…

Primary: Change in Messenger Ribonucleic Acid (mRNA) Transcriptome in Induced Sputum After 12, 28 and 84 Days of Treatment (Selected Probe Sets With Fold Change >1.5 or <-1.5 and…

Primary: Rate of Moderate or Severe Exacerbations — 1.49; 1.19; 1.27 Moderate/severe exacerbations per year — p=0.068

Primary: Number of Participants With Accurate Classification of Irreversible Airflow Obstruction — 10; 5 Participants

Primary: Change in Lung Function (Forced Expiratory Volume in 1 Second (FEV1) — 15.2; 20.1 percentage of change in FEV1